UMDF’s Comment to FDA’s Advisory Committee Regarding Elamipretide
Read UMDF’s Comment to FDA’s Advisory Committee regarding New Drug Application for Elamipretide in Barth...
Read: UMDF’s Comment to FDA’s Advisory Committee Regarding ElamipretideLatest News -Mito Advocacy
Advocacy Update – UMDF Co-Signs Letter Supporting PRV Reauthorization
UMDF Co-Signs Letter Supporting Rare Pediatric Disease Priority Review Voucher...
Read: Advocacy Update – UMDF Co-Signs Letter Supporting PRV ReauthorizationAdvocacy Update – Aug 2024: Help Shape the Legislative Landscape for the Mito Community Through Survey, UMDF Action Items
In a few weeks, we’ll join other mitochondrial disease-focused patient advocacy groups across the globe in marking World Mitochondrial Disease...
Read: Advocacy Update – Aug 2024: Help Shape the Legislative Landscape for the Mito Community Through Survey, UMDF Action ItemsUMDF Issues Response to Congressional 21st Century Cures Act RFI
UMDF Issues Response to Congressional 21st Century Cures Act RFI DOWNLOAD this document (PDF)...
Read: UMDF Issues Response to Congressional 21st Century Cures Act RFIAdvocacy Invite: FDA to Host Patient and Care Partner Perspectives on Safety Considerations for Approved Gene Therapy Treatments for Rare Diseases on Friday, September 20
As part of our commitment to raising patient voices in the regulatory process, we wanted to share an invite from the FDA’s Center for...
Read: Advocacy Invite: FDA to Host Patient and Care Partner Perspectives on Safety Considerations for Approved Gene Therapy Treatments for Rare Diseases on Friday, September 20Advocacy Update – July 2024: Watch Mito Caucus Briefing, A Win with NIH Language, and more
Last week, UMDF hosted a congressional briefing with the U.S. House of Representatives’ Mitochondrial Disease Caucus, which featured speakers...
Read: Advocacy Update – July 2024: Watch Mito Caucus Briefing, A Win with NIH Language, and moreAdvocacy Update – May 2024: FAA Reauthorization, Telehealth, Accelerating Kids’ Access to Care Act, and more
UMDF Advocacy Update – Dec. 2023 The House is scheduled to be out of session until January, while the Senate is scheduled to remain in...
Read: Advocacy Update – May 2024: FAA Reauthorization, Telehealth, Accelerating Kids’ Access to Care Act, and moreAdvocacy Update – February 2024: Redefining “Rare” For the World, Funding for 2024 & Beyond
UMDF Advocacy Update – Dec. 2023 The House is scheduled to be out of session until January, while the Senate is scheduled to remain in...
Read: Advocacy Update – February 2024: Redefining “Rare” For the World, Funding for 2024 & BeyondAdvocacy Update – January 2024: New FDA Guidance Encouraging Sign for Rare Disease Patients
UMDF Advocacy Update – Dec. 2023 The House is scheduled to be out of session until January, while the Senate is scheduled to remain in...
Read: Advocacy Update – January 2024: New FDA Guidance Encouraging Sign for Rare Disease Patients